ASSEMBLY BIOSCIENCES INC (ASMB) Fundamental Analysis & Valuation

NASDAQ:ASMB • US0453962070

Current stock price

27.87 USD
-0.46 (-1.62%)
At close:
27.87 USD
0 (0%)
After Hours:

This ASMB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ASMB Profitability Analysis

1.1 Basic Checks

  • In the past year ASMB has reported negative net income.
  • In the past year ASMB has reported a negative cash flow from operations.
  • In the past 5 years ASMB always reported negative net income.
  • In the past 5 years ASMB reported 4 times negative operating cash flow.
ASMB Yearly Net Income VS EBIT VS OCF VS FCFASMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • ASMB has a better Return On Assets (-2.38%) than 86.43% of its industry peers.
  • Looking at the Return On Equity, with a value of -2.96%, ASMB belongs to the top of the industry, outperforming 88.95% of the companies in the same industry.
Industry RankSector Rank
ROA -2.38%
ROE -2.96%
ROIC N/A
ROA(3y)-26.95%
ROA(5y)-48.05%
ROE(3y)-90.79%
ROE(5y)-92.37%
ROIC(3y)N/A
ROIC(5y)N/A
ASMB Yearly ROA, ROE, ROICASMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100

1.3 Margins

  • ASMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASMB Yearly Profit, Operating, Gross MarginsASMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ASMB Health Analysis

2.1 Basic Checks

  • ASMB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ASMB has more shares outstanding
  • Compared to 5 years ago, ASMB has more shares outstanding
  • ASMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ASMB Yearly Shares OutstandingASMB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
ASMB Yearly Total Debt VS Total AssetsASMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of 1.78, we must say that ASMB is in the distress zone and has some risk of bankruptcy.
  • ASMB has a Altman-Z score of 1.78. This is in the better half of the industry: ASMB outperforms 63.57% of its industry peers.
  • There is no outstanding debt for ASMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.78
ROIC/WACCN/A
WACC9.55%
ASMB Yearly LT Debt VS Equity VS FCFASMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 5.22 indicates that ASMB has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 5.22, ASMB is in line with its industry, outperforming 56.59% of the companies in the same industry.
  • A Quick Ratio of 5.22 indicates that ASMB has no problem at all paying its short term obligations.
  • ASMB has a Quick ratio (5.22) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.22
Quick Ratio 5.22
ASMB Yearly Current Assets VS Current LiabilitesASMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ASMB Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 88.99% over the past year.
  • The Revenue has grown by 153.52% in the past year. This is a very strong growth!
  • ASMB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.78% yearly.
EPS 1Y (TTM)88.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%257.96%
Revenue 1Y (TTM)153.52%
Revenue growth 3YN/A
Revenue growth 5Y-1.78%
Sales Q2Q%477.26%

3.2 Future

  • The Earnings Per Share is expected to decrease by -20.02% on average over the next years. This is quite bad
  • Based on estimates for the next years, ASMB will show a quite strong growth in Revenue. The Revenue will grow by 17.23% on average per year.
EPS Next Y-289.62%
EPS Next 2Y-66.59%
EPS Next 3Y-34.24%
EPS Next 5Y-20.02%
Revenue Next Year-81.22%
Revenue Next 2Y17.75%
Revenue Next 3Y5.41%
Revenue Next 5Y17.23%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ASMB Yearly Revenue VS EstimatesASMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
ASMB Yearly EPS VS EstimatesASMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. ASMB Valuation Analysis

4.1 Price/Earnings Ratio

  • ASMB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ASMB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASMB Price Earnings VS Forward Price EarningsASMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASMB Per share dataASMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • ASMB's earnings are expected to decrease with -34.24% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-66.59%
EPS Next 3Y-34.24%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ASMB Dividend Analysis

5.1 Amount

  • No dividends for ASMB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASMB Fundamentals: All Metrics, Ratios and Statistics

ASSEMBLY BIOSCIENCES INC

NASDAQ:ASMB (4/24/2026, 8:21:54 PM)

After market: 27.87 0 (0%)

27.87

-0.46 (-1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-19
Earnings (Next)05-06
Inst Owners57.55%
Inst Owner Change-0.22%
Ins Owners4.74%
Ins Owner Change1.8%
Market Cap442.02M
Revenue(TTM)72.30M
Net Income(TTM)-6.12M
Analysts86
Price Target49.73 (78.44%)
Short Float %14.68%
Short Ratio16.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)241.47%
Min EPS beat(2)8.89%
Max EPS beat(2)474.06%
EPS beat(4)4
Avg EPS beat(4)128.93%
Min EPS beat(4)4.47%
Max EPS beat(4)474.06%
EPS beat(8)8
Avg EPS beat(8)78.69%
EPS beat(12)9
Avg EPS beat(12)52.58%
EPS beat(16)10
Avg EPS beat(16)39.01%
Revenue beat(2)2
Avg Revenue beat(2)251.37%
Min Revenue beat(2)41.79%
Max Revenue beat(2)460.94%
Revenue beat(4)4
Avg Revenue beat(4)144.5%
Min Revenue beat(4)24.54%
Max Revenue beat(4)460.94%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.56%
PT rev (3m)2.09%
EPS NQ rev (1m)4.2%
EPS NQ rev (3m)21.38%
EPS NY rev (1m)18.85%
EPS NY rev (3m)18.85%
Revenue NQ rev (1m)-0.37%
Revenue NQ rev (3m)-0.37%
Revenue NY rev (1m)-67.95%
Revenue NY rev (3m)-67.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.11
P/FCF N/A
P/OCF N/A
P/B 2.14
P/tB 2.14
EV/EBITDA N/A
EPS(TTM)-0.74
EYN/A
EPS(NY)-2.88
Fwd EYN/A
FCF(TTM)-2.6
FCFYN/A
OCF(TTM)-2.59
OCFYN/A
SpS4.56
BVpS13.04
TBVpS13.04
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -2.38%
ROE -2.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.95%
ROA(5y)-48.05%
ROE(3y)-90.79%
ROE(5y)-92.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 51.16%
Cap/Sales 0.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.22
Quick Ratio 5.22
Altman-Z 1.78
F-Score5
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)43.18%
Cap/Depr(5y)162.88%
Cap/Sales(3y)1.25%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%257.96%
EPS Next Y-289.62%
EPS Next 2Y-66.59%
EPS Next 3Y-34.24%
EPS Next 5Y-20.02%
Revenue 1Y (TTM)153.52%
Revenue growth 3YN/A
Revenue growth 5Y-1.78%
Sales Q2Q%477.26%
Revenue Next Year-81.22%
Revenue Next 2Y17.75%
Revenue Next 3Y5.41%
Revenue Next 5Y17.23%
EBIT growth 1Y73.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.9%
EBIT Next 3Y6.46%
EBIT Next 5Y30.61%
FCF growth 1Y19.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.61%
OCF growth 3YN/A
OCF growth 5YN/A

ASSEMBLY BIOSCIENCES INC / ASMB Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ASSEMBLY BIOSCIENCES INC (ASMB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ASMB.


Can you provide the valuation status for ASSEMBLY BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to ASSEMBLY BIOSCIENCES INC (ASMB). This can be considered as Overvalued.


Can you provide the profitability details for ASSEMBLY BIOSCIENCES INC?

ASSEMBLY BIOSCIENCES INC (ASMB) has a profitability rating of 1 / 10.


What is the financial health of ASSEMBLY BIOSCIENCES INC (ASMB) stock?

The financial health rating of ASSEMBLY BIOSCIENCES INC (ASMB) is 6 / 10.